A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)

Clinical trial NCT04770779 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04770779
Sponsor: Agios Pharmaceuticals, Inc.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Transfusion-dependent Alpha-Thalassemia Transfusion-dependent Beta-Thalassemia

Start date: 2021-11-30
Primary completion: 2024-04-11
Enrollment: 258

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.